Blood Biomarkers: Democratizing Alzheimer’s Diagnostics
Copyright policy )Blood Biomarkers: Democratizing Alzheimer’s Diagnostics
Currently available biomarkers for Alzheimer's disease are of limited availability due to high costs and perceived invasiveness. New studies reveal that Alzheimer's pathologies now can be reliably quantified in vivo using regular blood tests.
- University of Gothenburg Sweden
- University College London United Kingdom
- UCL INSTITUTE OF NEUROLOGY United Kingdom
- Sahlgrenska University Hospital Sweden
- Sahlgrenska University Hospital Sweden
Amyloid beta-Peptides, Brain, Enzyme-Linked Immunosorbent Assay, tau Proteins, Health Services Accessibility, Peptide Fragments, Alzheimer Disease, Neurofilament Proteins, Positron-Emission Tomography, Humans, Phosphorylation, Biomarkers, Cerebrospinal Fluid
Amyloid beta-Peptides, Brain, Enzyme-Linked Immunosorbent Assay, tau Proteins, Health Services Accessibility, Peptide Fragments, Alzheimer Disease, Neurofilament Proteins, Positron-Emission Tomography, Humans, Phosphorylation, Biomarkers, Cerebrospinal Fluid
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).50 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
Citations provided by BIP!Popularity provided by BIP!